Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-28. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
=== Further reading === Philip J. Kocieński: Protecting Groups, 1st ed., Georg Thieme Verlag, Stuttgart 1994, ISBN 3-13-135601-4. Peter G.M. Wuts, Theodora W. Greene: Green's Protective Groups in Organic Synthesis, 4th Ed., John Wiley & Sons Inc., Hoboken, New Jersey, ISBN 0-471-69754-0. Michael Schelhaas, Herbert Waldmann: "Schutzgruppenstrategien in der organischen Synthese", in: Angewandte Chemie, 1996, 103, pp. 2192–2219; doi:10.1002/ange.19961081805 (in German). Krzysztof Jarowicki, Philip Kocieński: "Protecting groups", in: J. Chem. Soc., Perkin Trans. 1, 1998, pp. 4005–4037; doi:10.1039/A803688H.
Raw opium may be sold to a merchant or broker on the black market, but it usually does not travel far from the field before it is refined into morphine base, because the pungent, jelly-like form of raw opium is bulkier and harder to smuggle. Crude laboratories in the field are capable of refining opium into morphine base by a simple acid-base extraction. A sticky, brown paste, morphine base is pressed into bricks and sun-dried, and can either be smoked, prepared into other forms or processed into heroin. Other methods of preparation (besides smoking), include processing into regular opium tincture (tinctura opii), laudanum, paregoric (tinctura opii camphorata), herbal wine (e.g., vinum opii), opium powder (pulvis opii), opium sirup (sirupus opii) and opium extract (extractum opii). Vinum opii is made by combining sugar, white wine, cinnamon, and cloves. Opium syrup is made by combining 97.5 part sugar syrup with 2.5 parts opium extract. Opium extract (extractum opii) finally can be made by macerating raw opium with water. To make opium extract, 20 parts water are combined with 1 part raw opium which has been boiled for 5 minutes (the latter to ease mixing). Heroin is widely preferred because of increased potency. One study in postaddicts found heroin to be approximately 2.2 times more potent than morphine by weight with a similar duration; at these relative quantities, they could distinguish the drugs subjectively but had no preference. Heroin was also found to be twice as potent as morphine in surgical anesthesia.
DMG-PEG 2000 is a synthetic lipid formed by the PEGylation of myristoyl diglyceride. It is used to manufacture lipid nanoparticles that are used in mRNA vaccines, and in particular forms part of the drug delivery system for the Moderna COVID-19 vaccine.
Sources: en.wikipedia.org
== Pharmacodynamic properties == Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract, thus decreasing the constipating effects (slowing of gastrointestinal motility and transit, hypertonicity, increased fluid reabsorption) associated with opioids. If naloxegol is coadministered with other opioid antagonists, there is a potential for additive effect and increased risk of opioid withdrawal.
The CHMP recommended approval in April 2016, but the FDA rejected the application in November for having insufficient data in November 2016. The drug was authorized in the European Union in May 2016. Germany was the first country where migalastat was launched.
=== Asthma === Developing asthma due to abdominal obesity is also a main concern. As a result of breathing at low lung volume, the muscles are tighter and the airway is narrower. Obesity causes decreased tidal volumes due to a reduction in chest expansion that is caused both by the weight on the chest itself and the effect of abdominal obesity on flattening the diaphragm. It is commonly seen that people who are obese breathe quickly and often, while inhaling small volumes of air. People with obesity are also more likely to be hospitalized for asthma. A study has stated that 75% of patients treated for asthma in the emergency room were either overweight or obese.
Sources: en.wikipedia.org
=== Applied Radiation Corporation === In June 1960, High Voltage Engineering Corporation acquired Applied Radiation Corporation (ARCO) of Walnut Creek, California through a stock exchange. ARCO manufactured a line of linear accelerators with uses complementing those of HVEC's existing Van de Graaff accelerators. Applied Radiation was established as a separate subsidiary under its existing management, though its sales operations were integrated with HVEC's broader organization. The acquisition, however, would prove short-lived due to antitrust concerns. At the time, HVEC dominated the market for research accelerators, controlling an 80 percent share of orders. In April 1963, the Federal Trade Commission issued a consent decree requiring HVEC to divest itself of Applied Radiation Corporation. This forced divestiture reflected FTC concerns about concentration in the particle accelerator manufacturing industry, as both firms competed for research and industrial accelerator clients.
the establishment and maintenance of lot numbers; a standardized format for pedigree information; and the use of a common nomenclature for food with a goal of identifying each person who grows, produces, manufactures, processes, packs, transports, holds, or sells food in as short a timeframe as practicable but no longer than 2 business days. The measure has since died in the Senate. In parallel, the White House created a Food Safety Working Group which has issued statements calling for a national traceability system that would enhance traceability of all food, but without specifically endorsing a particular approach.
Renee and her son Sekou walk Jasmine down the aisle at her wedding with Crosby. Renee lives with Crosby, Jasmine, and Jabbar briefly when she loses her job, but moves out after a disagreement on how they discipline Jabbar. Renee insists that baby Aida should be baptized, and holds a baptism brunch at her place. She gets along well with Camille, and at the pre-baptism dinner at Zeek and Camille's house, says she always enjoys dinners that Camille holds. Gordon Flint (William Baldwin) was Adam's boss until he sold the company. When Sarah became an intern at Adam's company, she and Gordon became romantically involved, which caused friction between Adam and Sarah. Gordon is invited by Sarah to the Braverman Thanksgiving dinner, but that morning, when telling Adam he sold the company, Adam asks him not to come to the dinner. Gordon comes anyway, and at the football game that afternoon, tensions between Adam and Gordon come to a head. Mike (Kevin Alejandro), aka "Forklift Mike", drives a forklift at T&S Footwear. Mike recommends a band for Sarah to take Amber and Kelsey to see, at a club where Mike knows the man at the door. Alex (Michael B. Jordan) is Haddie's on again, off again boyfriend, whom she met while she volunteering at the food bank he currently manages. He is a recovering alcoholic and three years older than Haddie, so Haddie's parents initially disapprove of the relationship. Cory Smith (Anthony Carrigan) is Adam's new boss when Gordon sells the company. His youth and radical approach to business are disconcerting to Adam.
220 (5): 496.e1–496.e8. doi:10.1016/j.ajog.2019.01.218. PMID 30690015. S2CID 59342701. Sheng, C.; Jungverdorben, J.; Wiethoff, H.; Lin, Q.; Flitsch, L. J.; Eckert, D.; Hebisch, M.; Fischer, J.; Kesavan, J.; Weykopf, B.; Schneider, L.; Holtkamp, D.; Beck, H.; Till, A.; Wüllner, U.; Ziller, M. J.; Wagner, W.; Peitz, M.; Brüstle, O. (2018). "A Stably Self-Renewing Adult Blood-derived Induced Neural Stem Cell Exhibiting Pattern Ability and Epigenetic Rejuvenation". Nature Communications. 9 (1): 4047. Bibcode:2018NatCo...9.4047S. doi:10.1038/s41467-018-06398-5. PMC 6168501. PMID 30279449. López-Alcorocho, J. M.; Guillén-Vicente, I.; Rodríguez-Iñigo, E.; Guillén-Vicente, M.; Fernández-Jaén, T. F.; Caballero, R.; Casqueiro, M.; Najarro, P.; Abelow, S.; Guillén-García, P. (2019). "Study of Telomere Length in Preimplanted Cultured Chondrocytes". Cartilage. 10 (1): 36–42. doi:10.1177/1947603517749918. PMC 6376562. PMID 29322876. Salvador, L.; Singaravelu, G.; Harley, C. B.; Flom, P.; Suram, A.; Raffaele, J. M. (2016). "A Natural Product Telomerase Activator Lengthens Telomeres in Humans". Rejuvenation Research. 19 (6): 478–484. doi:10.1089/rej.2015.1793. PMC 5178008. PMID 26950204. Alda, M.; Puebla-Guedea, M.; Rodero, B.; Demarzo, M.; Montero-Marin, J.; Roca, M.; Garcia-Campayo, J. (2016). "Zen meditation, Length of Telomeres, and the Role of Experiential Avoidance and Compassion". Mindfulness. 7 (3): 651–659. doi:10.1007/s12671-016-0500-5. PMC 4859856. PMID 27217844. De Rooij, S. R.; Van Pelt, A. M.; Ozanne, S. E.; Korver, C. M.; Van Daalen, S. K.; Painter, R.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.